Antigenics Announces Exercise of Over-Allotment Option.Business Editors/Health/Medical Writers BIOWIRE2K NEW YORK--(BUSINESS WIRE)--Feb. 18, 2004 Antigenics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : AGEN) announced today that the underwriters of its recent public offering have purchased 400,000 shares of common stock pursuant to a partial exercise of their over-allotment option. The net proceeds Net Proceeds The amount received after all costs are deducted from the sale of a piece of property or security. Notes: In the case of an investor selling a security, net proceeds represent the proceeds from the sale minus any trading costs (i.e. commissions). to Antigenics from the sale of these 400,000 shares are approximately $4 million. The underwriters retain the right to acquire up to 350,000 more shares to cover additional over-allotments. UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Investment Bank acted as sole bookrunning manager of this offering, and Needham & Company, Inc. and Ryan Beck & Co., Inc. acted as co-managers. Antigenics is working to develop personalized immunotherapeutics and revolutionary treatments for cancers, infectious diseases infectious diseases: see communicable diseases. and autoimmune disorders Autoimmune Disorders Definition Autoimmune disorders are conditions in which a person's immune system attacks the body's own cells, causing tissue destruction. . This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion